Clinical trials: Cerebral Disorder
Colorectal Neoplasms
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
This trial will evaluate the safety and efficacy of vicriviroc (MK-7690) at 2 dose levels in combination with pembrolizumab (MK-3475) in participants with advanced/metastatic microsatellite stable (MSS) colorectal cancer (CRC).
- Trial name
- NCT03631407
- Testing
- Vicriviroc, Pembrolizumab
- Where
- 8 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Merck Sharp & Dohme LLC
Stroke
Smart Ankle-Foot Orthosis to Improve Stroke Outcomes: Smart AFO
The Smart Ankle-Foot Orthosis (Smart AFO) system is an investigational system that combines a diagnostic ankle-foot orthosis with a mobile application to assist clinicians in optimizing an AFO user's gait by adjusting AFO…
- Trial name
- NCT05619484
- Testing
- Smart AFO
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Orthocare Innovations, LLC
Primary Generalized Tonic-Clonic or Partial Onset Seizures, Lennox Gastaut Syndrome
An Extended Access Program (EAP) for Perampanel
The main objective of this EAP is to ensure that participants participating in Study E2007-G000-332, Study E2007-G000-311, E2007-G000-238, E2007-G000-338 or EAP E2007-G000-401 continue to have access to perampanel until such time…
- Trial name
- NCT02307578
- Testing
- Perampanel
- Where
- 27 sites in Belgium, Chile and 8 more
- Sponsor
- Eisai Inc.
Gait or Balance Disorder Problems
The CBF Study Evaluating the Effect of Betahistine on the Cerebral Blood Flow
Betahistine may provide benefit by enhancement of Cerebral Blood Flow (CBF). This placebo-controlled pharmacodynamic treatment study will primarily explore the effect of betahistine on cerebral blood flow measured by dynamic…
- Trial name
- CBF (NCT01468285)
- Testing
- betahistine dihydrochloride
- Where
- 2 sites in Singapore
- Volunteers
- 27 people
- Sponsor
- Abbott Products
Alzheimer Disease
Study to Evaluate DNL747 in Subjects With Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL747 in subjects with Alzheimer's disease when administered for 29 days in a cross-over design
- Trial name
- NCT03757325
- Testing
- DNL747
- Where
- 5 sites in United States, Netherlands
- Volunteers
- 16 people
- Sponsor
- Denali Therapeutics Inc.
Epilepsy
Pharmacokinetics, Efficacy and Tolerability of BIA 2-093
The purpose of this study is to characterize the pharmacokinetics of Eslicarbazepine acetate in children and adolescents with epilepsy.
- Trial name
- NCT02170064
- Testing
- BIA 2-093 (Eslicarbazepine acetate)
- Where
- Romania
- Volunteers
- 35 people
- Sponsor
- Bial - Portela C S.A.
Partial Epilepsy
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
- Trial name
- NCT05067634
- Testing
- Xcopri
- Where
- 35 sites in United States, Australia and 5 more
- Volunteers
- 154 people
- Sponsor
- SK Life Science, Inc.
Parkinson's Disease
PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral Tablets
The purpose of the study is to determine if the pharmacokinetic profile of V1512 is similar or better than existing medications for the treatment of Parkinson's Disease
- Trial name
- NCT00491998
- Testing
- V1512, V1512 and Entacapone
- Where
- Italy
- Volunteers
- 27 people
- Sponsor
- Vernalis (R&D) Ltd
Intracranial Aneurysm
Pipeline™ Vantage Embolization Device With Shield Technology™ for Wide-Necked Intracranial Aneurysms (ADVANCE)
The purpose of this study is to assess the safety and effectiveness of the Pipeline™ Vantage Embolization Device with Shield Technology™ in the treatment of intracranial aneurysms within the intended indication for use.
- Trial name
- ADVANCE (NCT03873714)
- Testing
- Pipeline™ Vantage Embolization Device with Shield Technology™
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Medtronic Neurovascular Clinical Affairs
Migraine Headache
MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)
A study to compare rizatriptan (MK0462) 5 mg by mouth (p.o.) and sumatriptan 50 mg p.o. for the acute treatment of a migraine attack.
- Trial name
- NCT00897104
- Testing
- rizatriptan benzoate (MK0462), Comparator: sumatriptan
- Volunteers
- 933 people
- Sponsor
- Organon and Co
Parkinson's Disease
Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment
The purposes of the study are to determine: i. To assess the efficacy of Tigan® (trimethobenzamide) in preventing nausea and vomiting when initiating therapy with Apokyn® (apomorphine) ii.
- Trial name
- NCT00489255
- Testing
- Tigan®
- Where
- 27 sites in United States
- Volunteers
- 117 people
- Sponsor
- Ipsen
Status Epilepticus, Convulsive Status EPILEPTICUS
Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus
This study will evaluate the effectiveness and safety of an investigational drug, IV ganaxolone, as adjunctive therapy to standard of care to treat subjects with status epilepticus.
- Conditions
- Status Epilepticus, Convulsive Status EPILEPTICUS, Non Convulsive Status Epilepticus, Epilepsy
- Trial name
- NCT03350035
- Testing
- IV Ganaxolone active
- Where
- 8 sites in United States
- Volunteers
- 17 people
- Sponsor
- Marinus Pharmaceuticals
Alzheimer Disease
A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of JNJ-54861911 in patients with prodromal Alzheimer's disease (pAD).
- Trial name
- NCT01978548
- Testing
- JNJ-54861911 10 mg, JNJ-54861911 50 mg
- Where
- 10 sites in Belgium, Netherlands and 2 more
- Volunteers
- 45 people
- Sponsor
- Janssen Research & Development, LLC
Stroke
PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement
To demonstrate that use of the Sentinel® Cerebral Protection System significantly reduces the risk of peri-procedural stroke (≤72 hours) after transcatheter aortic valve replacement (TAVR).
- Trial name
- PROTECTED TAVR (NCT04149535)
- Testing
- Sentinel® Cerebral Protection System
- Where
- 57 sites in United States, Australia and 4 more
- Volunteers
- 3,000 people
- Sponsor
- Boston Scientific Corporation
Fabry Disease
To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease
Primary Objective: To assess reduction of plasma lyso-GL3 level after switch to agalsidase beta from agalsidase alfa Secondary Objectives: To assess reduction of kidney podocyte GL3 content after switch to agalsidase beta from…
- Trial name
- BCLEAR1 (NCT04143958)
- Testing
- agalsidase beta (GZ419828), agalsidase alfa
- Sponsor
- Sanofi
Refractory Partial Epilepsy
Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures
This was a phase III 4-part study in multiple centres. Part I was a 26-week parallel-group, randomised, placebo-controlled period (8 weeks single-blind placebo baseline, 2 weeks double-blind titration, 12 weeks maintenance, and 4…
- Trial name
- NCT00957684
- Testing
- eslicarbazepine acetate
- Where
- Portugal
- Volunteers
- 402 people
- Sponsor
- Bial - Portela C S.A.
Traumatic Brain Injury
Crainio Non-invasive ICP Monitor for TBI
The clinical investigation aims to advance the Crainio device, designed for non-invasive intracranial pressure (ICP) monitoring.
- Trial name
- NCT06453733
- Testing
- Crainio
- Where
- United Kingdom
- Volunteers
- 54 people
- Sponsor
- Crainio Ltda
Mild Cognitive Impairment
Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.
Glutamate is fundamentally involved in learning and memory. Memory loss associated with mild cognitive impairment may be due to loss of glutamate receptors in the aging brain.
- Trial name
- NCT00040443
- Testing
- CX516
- Where
- 8 sites in United States
- Volunteers
- 175 people
- Sponsor
- RespireRx
Cardiac Diseases, Muscular Weakness
Biomarker for Pompe Disease (BioPompe)
Development of a new MS-based biomarker for the early and sensitive diagnosis of Pompe disease from blood (plasma)
- Conditions
- Cardiac Diseases, Muscular Weakness, Hepato-splenomegaly, Lung Disease
- Trial name
- BioPompe (NCT01457443)
- Where
- 4 sites in Germany, India and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
Intracranial Aneurysm
To Evaluate the Safety and Efficacy of Intracranial Stent Assisted Endovascular Treatment of Intracranial Aneurysms
The purpose of this study is to assess safety and effectiveness of the pEGASUS stent system.
- Trial name
- NCT06158087
- Testing
- pEGASUS Stent System
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Shanghai Wallaby Medical Technologies Co.,Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.